Gambacorti‐Passerini, C., Brümmendorf, T. H., Kim, D., Turkina, A. G., Masszi, T., Assouline, S., Durrant, S., Kantarjian, H. M., Khoury, H. J., Zaritskey, A., Shen, Z., Jin, J., Vellenga, E., Pasquini, R., Mathews, V., Cervantes, F., Besson, N., Turnbull, K., Leip, E., Kelly, V., & Cortes, J. E. (n.d.). bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up. American journal of hematology, 89(7), 732–742. http://access.bl.uk/ark:/81055/vdc_100024867531.0x00005d